3rd Quarter - Report

THE KPM GROUP DC LLC for RARE DISEASE COMPANY COALITION

Firm
Client
Income
$140,000
Expenses
—

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

H.R. 7384, Creating Hope Reauthorization Act S.2372/H.R.4758, Accelerating Kids Access to Care Act H.R.6664, Innovation in Pediatric Drugs Act of 2023 H.R.5539/S.3131, the ORPHAN Cures Act H.R.1184/S.4071, the Helping Experts Accelerate Rare Treatments Act S.526/H.R.1092, the BENEFIT Act S.350/H.R.482, the Newborn Screening Saves Lives Reauthorization Act H.R.3433/S.2897, the Give Kids a Chance Act

LobbyistCovered position, as disclosed
STACEY FRISK —
PAULA GUTIERREZ New —
YOKO ROSENBAUM —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Natl Institutes of Health (NIH)

Bills named: H.R. 6664 (118th), H.R. 7384 (118th), H.R. 1092 (118th), S. 2897 (118th), H.R. 482 (118th), H.R. 3433 (118th), S. 4071 (118th), H.R. 1184 (118th), H.R. 4758 (118th), S. 526 (118th), H.R. 5539 (118th), S. 3131 (118th), S. 2372 (118th), S. 350 (118th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.